Privi Speciality Chemicals Q1 FY27: Profit up 36% YoY

Q1 FY27 results set the tone for FY27

Privi Speciality Chemicals reported a strong start to FY27, helped by faster profit growth than revenue. For the quarter ended June 30, 2026 (Q1 FY27), consolidated revenue from operations rose 19.22% year-on-year to ₹666.22 crore. Consolidated net profit attributable to owners increased 35.97% to ₹84.21 crore. Management linked the stronger profit growth to lower finance costs and better capital efficiency. The performance comes alongside a broader push to simplify the group structure and move further into higher-value specialty molecules. The company also reiterated a large medium-term growth plan during the earnings discussion. The quarterly print and the strategic roadmap together provide a clearer picture of Privi’s near-term execution and longer-term ambitions.

What management highlighted behind profit growth

Management said profit grew faster than revenue due to lower finance costs and improved capital efficiency. That combination typically supports margins without requiring outsized top-line acceleration. In this quarter, the company’s profit growth of 35.97% materially outpaced the 19.22% rise in revenue. The commentary points to cost-of-capital and balance-sheet efficiency being key levers, rather than only volume growth. The company also spoke about stepping up its focus on higher-value specialty molecules, which can potentially support profitability if executed well. Beyond operating levers, Privi is working on simplifying its corporate structure via a merger, aimed at improving operational coordination. The quarter’s numbers and management’s narrative together suggest FY27 priorities are not limited to growth, but also to capital allocation and structure.

Medium-term targets: FY29-30 revenue and EBITDA goals

On the latest earnings call, management reinforced a more ambitious medium-term target for the business. The company is targeting ₹5,000 crore in revenue by FY29-30. It also set an EBITDA goal of more than ₹1,000 crore by FY29-30. These targets indicate the scale of growth the company is planning over the next few years. The targets were shared alongside discussions on capacity additions and portfolio upgrading. While the company did not provide quarter-wise milestones in the provided details, the direction was clear: scale-up with a higher share of specialty offerings. Investors typically track whether capex timelines, capacity ramp-ups, and product mix changes align with such targets. Any future disclosures on commissioning schedules and utilization trends will likely be key reference points against this stated ambition.

Expansion plan of ₹850-900 crore

Privi outlined an expansion plan in the range of ₹850 crore to ₹900 crore. The plan was presented alongside its push into higher-value specialty molecules and a broader growth roadmap. A capex programme of this size can affect near-term cash flows and leverage metrics, depending on the pace of execution and funding mix. Management also linked the quarter’s stronger profit growth to lower finance costs, which makes the cost of funding a key variable as expansion progresses. The company has not detailed project-level breakups in the provided text, but it positioned the investment as part of its scaling plan. The market generally evaluates such programmes on timelines, returns, and the stability of end-demand for the added capacity. As disclosed, the capex range sets the outer band of the investment commitment.

Merger filing aims to simplify structure and add capacity

The company’s scheme of amalgamation involving Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited was filed before the NCLT Mumbai Bench on June 25, 2026. This filing came after both stock exchanges issued no-objection letters. Management said the consolidation is expected to simplify the group structure and unlock operational synergies. The proposed merger is also expected to add around 6,000 metric tons of capacity to the portfolio. Management expects the merger to be completed within the current financial year. If completed as guided, investors may look for clearer segment reporting and streamlined operations post-integration. The merger effort sits alongside capex plans, suggesting a parallel approach of adding capacity while reducing structural complexity.

Board approvals and SEBI disclosure compliance

The Board approved the unaudited financial results at its meeting held on July 30, 2026. The approval was made pursuant to Regulation 30 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such board approvals and disclosures are standard for listed companies, but they establish the formal record of results and governance processes. The company repeated the same approval details in its communications, underscoring compliance. In addition to quarterly results, the company has been communicating merger-related filings and dividend actions through exchange disclosures. For investors, the clustering of results, merger progress, and dividend calendar updates provides multiple corporate triggers within a short period. The disclosures also include AGM and voting schedules that determine shareholder participation.

Dividend, record date, AGM, and payout timeline

The Board had recommended a final dividend of ₹10 per equity share (face value ₹10 each) for FY 2025-26. The final dividend aggregates to ₹39.06 crore, subject to shareholder approval at the 41st annual general meeting. The company fixed July 31, 2026 as the record date for determining shareholder entitlement. The 41st AGM is scheduled for August 7, 2026 at 4:00 p.m. IST via video conferencing and other audio-visual means. Remote e-voting is available from August 4, 2026 (9:00 a.m. IST) to August 6, 2026 (5:00 p.m. IST). If approved, the dividend is scheduled to be paid on or before September 5, 2026, subject to tax deduction at source. The Register of Members and Share Transfer Books will remain closed from August 1, 2026 to August 7, 2026, both days inclusive.

FY26 backdrop and reference financial metrics

The company also reported strong FY26 performance in its earlier disclosures. Consolidated PAT for FY26 rose 75.2% to ₹327.54 crore, while revenue grew 21.7% to ₹2,582.92 crore. In another set of disclosed figures, FY26 revenue from operations was reported at ₹2,455.53 crore, up 20.47% year-on-year from ₹2,038.34 crore in FY25, and FY26 total income was ₹2,472.42 crore versus ₹2,056.25 crore in FY25. For Q4 FY26, revenue from operations was reported at ₹660.35 crore, and profit before tax at ₹137.85 crore, with Q4 FY26 EPS at ₹26.30 and FY26 EPS at ₹91.50. The mix of standalone and consolidated disclosures across updates means investors generally track the context of each metric carefully. Still, the set of figures shows that the business entered FY27 after a high-growth FY26 base. The Q1 FY27 performance continues that momentum, at least on year-on-year comparisons.

Governance items: directors and auditors

The AGM agenda includes re-appointment of Mr. Mahesh Purshottam Babani as a Director retiring by rotation. The Board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director (Whole-time Director) for three years, effective from August 13, 2026 to August 12, 2029, subject to shareholder approval. The company disclosed re-appointment of M/s Aneja Associates as Internal Auditors and M/s Kishore Bhatia & Associates as Cost Auditors for FY 2026-27. It also disclosed ratification of cost auditor remuneration of ₹0.09 crore per annum (₹9,00,000). These items are routine but important from a continuity and oversight perspective. For investors, such governance disclosures also indicate how the board is structuring accountability as the company executes a large capex programme and merger integration.

Key numbers at a glance

Corporate calendar: dividend and AGM schedule

Why the update matters for investors

This update combines three investor-relevant threads: quarterly performance, capital investment intent, and corporate actions. Q1 FY27 showed a faster rise in profit than revenue, which management attributed to lower finance costs and better capital efficiency. The capex range of ₹850-900 crore and the FY29-30 targets of ₹5,000 crore revenue and more than ₹1,000 crore EBITDA establish a clear scale of ambition. The merger filing before NCLT and the expected addition of around 6,000 metric tons of capacity provide a structural and operational lens to how the company intends to grow. Separately, the ₹10 per share final dividend, the July 31 record date, and the August 7 AGM schedule outline near-term shareholder timelines. With multiple items moving in parallel, future exchange disclosures on merger approvals and capex execution milestones will be key signposts.

Conclusion

Privi Speciality Chemicals opened FY27 with consolidated revenue of ₹666.22 crore and net profit of ₹84.21 crore in Q1, supported by lower finance costs and improved capital efficiency. Alongside results, it reiterated an ₹850-900 crore expansion plan, a merger-led simplification effort, and FY29-30 targets of ₹5,000 crore revenue and more than ₹1,000 crore EBITDA. The amalgamation scheme was filed with the NCLT Mumbai Bench on June 25, 2026, and management expects completion within the current financial year, with an estimated ~6,000 metric tons capacity addition. The company’s final dividend of ₹10 per share for FY26 will be put to shareholders at the 41st AGM on August 7, 2026, with July 31, 2026 as the record date and payment on or before September 5, 2026 if approved. The next set of formal updates is likely to come through AGM outcomes and the regulatory process for the merger.